257 related articles for article (PubMed ID: 31252171)
1. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
2. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
[TBL] [Abstract][Full Text] [Related]
3. Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy.
Feng X; Yao J; Gao X; Jing Y; Kang T; Jiang D; Jiang T; Feng J; Zhu Q; Jiang X; Chen J
ACS Appl Mater Interfaces; 2015 Dec; 7(50):27885-99. PubMed ID: 26619329
[TBL] [Abstract][Full Text] [Related]
4. The synergistic effect of folate and RGD dual ligand of nanographene oxide on tumor targeting and photothermal therapy in vivo.
Jang C; Lee JH; Sahu A; Tae G
Nanoscale; 2015 Nov; 7(44):18584-94. PubMed ID: 26489965
[TBL] [Abstract][Full Text] [Related]
5. Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer.
Wang J; Wang C; Li Y; Li M; Zhu T; Shen Z; Wang H; Lv W; Wang X; Cheng X; Xie X
Clin Transl Med; 2021 May; 11(5):e425. PubMed ID: 34047469
[TBL] [Abstract][Full Text] [Related]
6. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Wang Y; Liu P; Duan Y; Yin X; Wang Q; Liu X; Wang X; Zhou J; Wang W; Qiu L; Di W
Biomaterials; 2014 Jan; 35(3):983-92. PubMed ID: 24176193
[TBL] [Abstract][Full Text] [Related]
7. Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration.
Xiao X; Yang M; Xiao J; Zou J; Huang Q; Yang K; Zhang B; Yang F; Liu S; Wang H; Bai P
Cancer Chemother Pharmacol; 2014 Apr; 73(4):807-18. PubMed ID: 24638862
[TBL] [Abstract][Full Text] [Related]
8. Ursolic acid-loaded chitosan nanoparticles induce potent anti-angiogenesis in tumor.
Jin H; Pi J; Yang F; Wu C; Cheng X; Bai H; Huang D; Jiang J; Cai J; Chen ZW
Appl Microbiol Biotechnol; 2016 Aug; 100(15):6643-6652. PubMed ID: 26883344
[TBL] [Abstract][Full Text] [Related]
9. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
10. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
[TBL] [Abstract][Full Text] [Related]
11. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
[TBL] [Abstract][Full Text] [Related]
12. Pre-coating cRGD-modified bovine serum albumin enhanced the anti-tumor angiogenesis of siVEGF-loaded chitosan-based nanoparticles by manipulating the protein corona composition.
Wu Z; Yuan C; Xia Q; Qu Y; Yang H; Du Q; Xu B
Int J Biol Macromol; 2024 May; 267(Pt 2):131546. PubMed ID: 38614172
[TBL] [Abstract][Full Text] [Related]
13. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.
Park K; Kim YS; Lee GY; Park RW; Kim IS; Kim SY; Byun Y
Pharm Res; 2008 Dec; 25(12):2786-98. PubMed ID: 18581207
[TBL] [Abstract][Full Text] [Related]
14. Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery.
Huang P; Liu J; Wang W; Zhang Y; Zhao F; Kong D; Liu J; Dong A
Acta Biomater; 2016 Aug; 40():263-272. PubMed ID: 26607767
[TBL] [Abstract][Full Text] [Related]
15. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
Adulnirath A; Chung SW; Park J; Hwang SR; Kim JY; Yang VC; Kim SY; Moon HT; Byun Y
J Control Release; 2012 Nov; 164(1):8-16. PubMed ID: 23063549
[TBL] [Abstract][Full Text] [Related]
16. CEACAM6 promotes tumor angiogenesis and vasculogenic mimicry in gastric cancer via FAK signaling.
Zang M; Zhang Y; Zhang B; Hu L; Li J; Fan Z; Wang H; Su L; Zhu Z; Li C; Yan C; Gu Q; Liu B; Yan M
Biochim Biophys Acta; 2015 May; 1852(5):1020-8. PubMed ID: 25703140
[TBL] [Abstract][Full Text] [Related]
17. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
18. Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma.
Cai X; Wang Z; Lin S; Chen H; Bu H
Phytomedicine; 2024 Apr; 126():155402. PubMed ID: 38350242
[TBL] [Abstract][Full Text] [Related]
19. The deubiquitinase USP7 and E3 ligase TRIM21 regulate vasculogenic mimicry and malignant progression of RMS by balancing SNAI2 homeostasis.
Zhang R; Zhang D; Han F; Song X; Zhang Y; Zhang J; Zhu Q; Qin Y
J Exp Clin Cancer Res; 2024 May; 43(1):135. PubMed ID: 38702792
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma.
Du J; Sun B; Zhao X; Gu Q; Dong X; Mo J; Sun T; Wang J; Sun R; Liu Y
Gynecol Oncol; 2014 Jun; 133(3):575-83. PubMed ID: 24589413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
